Showing results (31-40 of 73) with videos related to

Sort By:
Pageof 8
Biorxiv : the Preprint Server for Biology|December 25, 2025
Mind the gap: Understanding discordance between culture- and a non-culture-based measure of bacterial burden in murine tuberculosis treatment modelsSamuel T Tabor, Allan D Friesen, Matthew J Reichlen, et al.
Biorxiv : the Preprint Server for Biology|April 3, 2026
Adaptive immunity shapes baseline physiology of <i>M. tuberculosis</i> in high-dose versus low-dose infection BALB/c mouse drug treatment modelsJo Hendrix, Reem Al Mubarak, Karen Rossmassler, et al.
ACS Infectious Diseases|January 10, 2025
Anti-Mycobacterial Activity of Bacterial Topoisomerase Inhibitors with Dioxygenated LinkersMark J Mitton-Fry, Jason E Cummings, Yanran Lu, et al.
The Journal of Antimicrobial Chemotherapy|December 22, 2016
Spectinamides are effective partner agents for the treatment of tuberculosis in multiple mouse infection modelsGregory T Robertson, Michael S Scherman, David F Bruhn, et al.
Biorxiv : the Preprint Server for Biology|September 4, 2024
Emergence of antibiotic-specific <i>Mycobacterium tuberculosis</i> phenotypes during prolonged treatment of miceElizabeth A Wynn, Christian Dide-Agossou, Reem Al Mubarak, et al.
Antimicrobial Agents and Chemotherapy|September 18, 2025
Deconvoluting drug interactions using <i>M. tuberculosis</i> physiologic processes: transcriptional disaggregation of the BPaL regimen <i>in vivo</i>Elizabeth A Wynn, Christian Dide-Agossou, Reem Al Mubarak, et al.
Antimicrobial Agents and Chemotherapy|January 17, 2025
Emergence of antibiotic-specific <i>Mycobacterium tuberculosis</i> phenotypes during prolonged treatment of miceElizabeth A Wynn, Christian Dide-Agossou, Reem Al Mubarak, et al.
Pharmaceutics|June 28, 2023
Development of a Minimalistic Physiologically Based Pharmacokinetic (mPBPK) Model for the Preclinical Development of Spectinamide AntibioticsKeyur R Parmar, Pradeep B Lukka, Santosh Wagh, et al.
Antimicrobial Agents and Chemotherapy|March 26, 2025
Contribution of front-line, standard-of-care drugs to bactericidal responses, resistance emergence, and cure in murine models of easy- or hard-to-treat tuberculosis diseaseNathan Peroutka-Bigus, Elizabeth J Brooks, Michelle E Ramey, et al.
Antimicrobial Agents and Chemotherapy|January 15, 2026
A modeling-based framework to evaluate forgiveness of tuberculosis treatment in a BALB/c relapsing mouse modelSylvie Sordello, Laure Brock, Alessia Tagliavini, et al.
Pageof 8